Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Three recent well-designed clinical trials demonstrated that tiotropium bromide, when added to an inhaled corticosteroid (ICS), provides asthma control which is non-inferior to adding a long-acting β-agonist (LABA).1–⇓3 The third of these trials also suggested that adding tiotropium to an ICS–LABA combination also provides additional benefit, as measured by an improvement in lung function (FEV1).3 Whether adding tiotropium to patients inadequately controlled on combination ICS–LABA therapy would provide additional benefit by improving long-term asthma control and decreasing severe asthma exacerbations was the subject of …
Competing interests SPP has received grants from NHLBI (AsthmaNet, SARP, SPIROMICS), the American Lung Association (Asthma Clinical Research Centers) and is an Advisor to DCC. He serves as a consultant to AstraZeneca, Aerocrine, Airsonett AB, GlaxoSmithKline, Merck, Targacept and TEVA and has provided lectures for Merck and Integrity CE.